. Author manuscript; available in PMC: 2015 Jun 1.

Published in final edited form as: Cancer Immunol Res. 2014 Feb 20;2(6):530–537. doi: 10.1158/2326-6066.CIR-13-0180

Table 1.

Univariate analysis of clinicopathological and immune characteristics for survival and recurrence

				OS		TTR

Variables	Cut-off	n	(%)	(months)	p -value	(months)	p -value

Clinicopathological
Age	> 63	79	50	40.3	0.06	17.5	0.03
	≤ 63	79	50	50.6		18.5

Gender	Male	90	57	42.7	0.9	18.5	0.6
	Female	68	43	45.6		17.7

Site of primary Ca.	Colon	101	64	40.3	0.2	16.8	0.9
	Rectum	57	36	50.1		21.2

Perioperative chemotherapy	Yes	139	89	45.6	0.8	17.7	0.5
	No	17	11	36.9		59.9

Major resection (≥ 3 segments)	No	66	42	55.0	0.02	16.9	0.09
	Yes	92	58	38.5		27.1

Cancer at resection margin	Negative	141	91	49.5	<0.001	18.8	0.04
	Positive	14	9	19.6		10.1

No. of hepatic metastasis^a,^b	Solitary	79	50	53.0	0.008	22.5	0.05
	> 1	79	50	37.4		15.7

Size of largets tumor (cm)^a	≤ 5	106	67	53.7	0.003	21.7	0.13
	> 5	52	33	33.3		15.0

Preoperative CEA (ng/ml)^a	≤ 200	125	85	50.0	0.001	19.0	0.002
	> 200	22	15	26.6		10.4

Node-positive primary^a	No	52	33	67.8	0.005	46.0	0.002
	Yes	106	67	41.2		15.9

DFI (months)^a	≥ 12	88	56	53.7	0.04	22.5	0.07
	< 12	70	44	39.6		15.8

Clinical Risk Score	0 or 1	53	35	77.4	<0.001	31.4	<0.001
	2	48	31	50.6		21.4
	≥ 3	52	34	26.6		10.2

Immune features^c
MHC-I	High	40	25	89.0	0.13	83.7	0.04
	Low	118	75	40.1		21.5

β2m	High	63	40	53.4	0.64	25.3	0.44
	Low	94	60	40.1		16.9

CD3	High	36	23	67.1	0.7	18.5	0.97
	Low	118	77	43.7		18.4

CD4	High	32	21	110.9	0.02	76.9	0.21
	Low	123	79	40.3		17.0

CD8	High	39	25	89.7	0.09	46.0	0.38
	Low	116	75	40.1		17.0

Combination of immune features
MHC-I^hiCD3^hi	Yes	31	20	115.9	0.001	NR	0.008
	No	123	80	40.3		17.1

MHC-I^hiCD4^hi	Yes	30	19	105.7	0.001	NR	0.001
	No	125	81	39.6		16.9

MHC-I^hiCD8^hi	Yes	31	20	89.7	0.008	NR	0.02
	No	124	80	40.1		17.0

NOTE: Log-rank test, median overall survival and time-to-recurrence.

Clinicopathological features used to calculate the Clinical Risk Score.

Only continuous variable significantly associated with OS and TTR at a level of p≤ .05 (Cox regression).

Optimal cut-off points by maximally selected chi-square method, and p-values corrected for over-fitting.

Abbreviations: β2m, Beta-2 microglobulin; CEA, carcinoembryonic antigen; DFI, disease-free interval; MHC-I, MHC class I; NR, not reached; OS, overall survival; TTR, time to recurrence